

PARP Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

<https://marketpublishers.com/r/P0D7E9858458EN.html>

Date: September 2025

Pages: 76

Price: US\$ 3,200.00 (Single User License)

ID: P0D7E9858458EN

Abstracts

PARP Inhibitor Market Summary

The poly (ADP-ribose) polymerase (PARP) inhibitor market is an important segment of the global oncology therapeutics landscape, focusing on targeted therapies that address cancers associated with defects in DNA damage repair mechanisms. PARP inhibitors function by blocking the PARP enzyme, which normally repairs single-strand breaks in DNA. In cancer cells with mutations in homologous recombination repair genes such as BRCA1/2, this inhibition leads to the accumulation of DNA damage and subsequent cell death. The approach has been particularly effective in patients with breast cancer, ovarian cancer, fallopian tube cancer, and prostate cancer, although applications continue to expand into other indications through ongoing clinical development. The market has seen steady progress since the first approvals in ovarian cancer and has developed into a multi-billion-dollar segment within oncology. By 2025, the global PARP inhibitor market is projected to reach a value of USD 5–8 billion, supported by rising cancer incidence, expanded label indications, and ongoing clinical adoption. Growth through 2030 is expected to remain robust with a compound annual growth rate (CAGR) of 4.0%–7.4%. Patent expirations of leading products will reshape the competitive landscape, creating both challenges and opportunities for established pharmaceutical companies and new entrants.

Regional Market Trends

The regional dynamics of the PARP inhibitor market are shaped by cancer epidemiology, regulatory approvals, healthcare infrastructure, and reimbursement frameworks.

North America: The United States dominates the global PARP inhibitor market, supported by high incidence of ovarian and breast cancers, advanced molecular diagnostics, and rapid adoption of targeted therapies. Growth in this region is estimated at 3.5%–6.0% CAGR through 2030. Canada also contributes, with universal healthcare access enabling availability of novel oncology drugs, though pricing pressures are more significant compared to the U.S.

Europe: Key markets include Germany, the United Kingdom, France, and Italy. Growth is estimated at 3.8%–6.5% CAGR. Europe benefits from robust regulatory support through the EMA and widespread integration of PARP inhibitors into treatment guidelines for ovarian and breast cancers. Patent expirations in this region during 2027–2029 are expected to encourage earlier entry of generics and biosimilars, influencing competitive dynamics and access.

Asia-Pacific: With a projected growth rate of 5.0%–8.0%, this region represents the fastest-growing market for PARP inhibitors. China and Japan are the major contributors, with China's large cancer population and rapidly expanding healthcare infrastructure driving demand. Patent expiry of olaparib in China has already opened opportunities for local generics. Japan, with high adoption of innovative oncology therapies, also remains a key market. India, South Korea, and Australia are emerging contributors as access to oncology diagnostics improves.

Latin America: Countries such as Brazil and Mexico are seeing steady growth at an estimated CAGR of 3.5%–6.0%. Improving cancer care infrastructure and government-led initiatives to expand access to targeted therapies support demand, although reimbursement challenges remain a barrier to widespread adoption.

Middle East and Africa (MEA): Growth is estimated at 3.0%–5.5% CAGR. South Africa, Saudi Arabia, and the UAE are leading adopters, supported by improving oncology care networks and participation in international clinical trials. However, cultural, economic, and infrastructure barriers continue to limit broader uptake across much of the region.

Application Analysis

The market for PARP inhibitors is segmented by therapeutic application, with breast

cancer and ovarian cancer representing the largest opportunities, followed by fallopian tube cancer, prostate cancer, and other indications.

Breast Cancer: A leading application area with strong demand, driven by patients with BRCA1/2 mutations. PARP inhibitors are increasingly used in both metastatic and earlier-stage disease. Growing use of genetic testing is expected to further expand adoption.

Ovarian and Fallopian Tube Cancer: Ovarian cancer was the first approved indication for PARP inhibitors and continues to be a cornerstone of the market. Maintenance therapy following platinum-based chemotherapy remains a strong driver, with adoption in both newly diagnosed and recurrent cases.

Prostate Cancer: This represents a growing segment, with PARP inhibitors being integrated into treatment pathways for metastatic castration-resistant prostate cancer patients with DNA repair gene mutations. Rising prostate cancer incidence globally and new approvals will support expansion.

Others: Research is ongoing to extend the application of PARP inhibitors into other cancers, including pancreatic cancer and gastric cancer. While still early-stage, these indications may provide incremental growth opportunities.

Type Analysis

The PARP inhibitor market is structured around several leading products, each with unique positioning:

Olaparib (LYNPARZA®): Co-developed by Merck & Co. and AstraZeneca, olaparib dominates the market with broad label coverage across ovarian, breast, pancreatic, and prostate cancers. Revenue in 2024 was USD 4.5–5.5 billion. Patent expirations in China have already opened opportunities for generics, while patents in the U.S., Europe, and Japan are expected to expire between 2027 and 2029.

Niraparib (Zejula®): Marketed by GlaxoSmithKline, niraparib is approved for ovarian cancer treatment and maintenance therapy. Revenues in 2024 reached USD 0.6–0.7 billion. Ongoing clinical trials are evaluating its role in combination therapies, which may extend its use.

Talazoparib (TALZENNA®): Pfizer's talazoparib is used for HER2-negative breast cancer and has generated revenues of USD 0.1–0.2 billion in 2024. Expansion into prostate cancer treatment through combinations with other targeted agents is a key focus for growth.

Rucaparib (RUBRACA®): Licensed to pharma& Schweiz GmbH and commercialized by Tolmar, rucaparib is indicated for ovarian and prostate cancers. While its market share is smaller compared to olaparib and niraparib, it remains an important option within the class.

Company Profiles

Merck & Co. / AstraZeneca: Market leaders with olaparib, which commands the largest share of the PARP inhibitor space. Their extensive clinical trial network and combination therapy research ensure continued leadership despite patent expirations.

GlaxoSmithKline: Strong in ovarian cancer with niraparib, and investing heavily in expanding applications. Its focus on women's health and oncology strengthens its strategic position.

Pfizer: Growing its oncology presence with talazoparib and leveraging its global commercialization network. Combination studies with androgen receptor inhibitors in prostate cancer are central to its growth strategy.

pharma& Schweiz GmbH: Through rucaparib, the company maintains a niche presence in ovarian and prostate cancers, with licensing agreements supporting its commercialization.

Industry Value Chain Analysis

The value chain for PARP inhibitors spans multiple stages:

Research and Development: Involves discovery of targeted compounds, biomarker-driven clinical trials, and regulatory approvals. Extensive collaboration between pharmaceutical companies, academic institutions, and biotechnology

firms characterizes this stage.

Manufacturing: Requires high-quality active pharmaceutical ingredients (APIs) and adherence to stringent GMP standards for oral oncology drugs.

Distribution and Access: Large multinational companies distribute through specialty pharmacies, hospitals, and oncology clinics. Access programs and patient assistance initiatives are critical in emerging markets.

Clinical Adoption and Monitoring: Oncologists play a central role in prescribing, supported by genetic testing to identify eligible patients. Pharmacovigilance and long-term monitoring of safety and efficacy remain integral.

Opportunities and Challenges

Opportunities:

Expansion into earlier stages of cancer treatment and additional indications beyond ovarian and breast cancers.

Growing demand in emerging markets, particularly in Asia-Pacific, where cancer incidence is rising rapidly.

Combination therapy strategies, pairing PARP inhibitors with immune checkpoint inhibitors or targeted therapies, which may expand efficacy.

Advances in companion diagnostics, enabling precision medicine approaches and more targeted use.

Challenges:

Patent expirations of leading products between 2027 and 2029, opening the market to generic competition.

Cost and reimbursement pressures, particularly in Europe and emerging markets, which may limit broad adoption.

Safety concerns, including hematologic toxicities and gastrointestinal

side effects, which can restrict long-term use.

Competition from alternative therapies, including next-generation targeted drugs and immunotherapies, which may erode market share.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 PARP Inhibitor Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST PARP INHIBITOR MARKET IN NORTH AMERICA (2020-2030)

- 8.1 PARP Inhibitor Market Size
- 8.2 PARP Inhibitor Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 PARP Inhibitor Market Size by Type
- 8.5 Key Countries Analysis
 - 8.5.1 United States
 - 8.5.2 Canada
 - 8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST PARP INHIBITOR MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 PARP Inhibitor Market Size
- 9.2 PARP Inhibitor Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 PARP Inhibitor Market Size by Type
- 9.5 Key Countries Analysis
 - 9.5.1 Brazil
 - 9.5.2 Argentina

CHAPTER 10 HISTORICAL AND FORECAST PARP INHIBITOR MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 PARP Inhibitor Market Size
- 10.2 PARP Inhibitor Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 PARP Inhibitor Market Size by Type
- 10.5 Key Countries Analysis
 - 10.5.1 China
 - 10.5.2 India
 - 10.5.3 Japan
 - 10.5.4 South Korea
 - 10.5.5 Southeast Asia

10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST PARP INHIBITOR MARKET IN EUROPE (2020-2030)

11.1 PARP Inhibitor Market Size

11.2 PARP Inhibitor Market by End Use

11.3 Competition by Players/Suppliers

11.4 PARP Inhibitor Market Size by Type

11.5 Key Countries Analysis

11.5.1 Germany

11.5.2 France

11.5.3 United Kingdom

11.5.4 Italy

11.5.5 Spain

11.5.6 Belgium

11.5.7 Netherlands

11.5.8 Austria

11.5.9 Poland

11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST PARP INHIBITOR MARKET IN MEA (2020-2030)

12.1 PARP Inhibitor Market Size

12.2 PARP Inhibitor Market by End Use

12.3 Competition by Players/Suppliers

12.4 PARP Inhibitor Market Size by Type

CHAPTER 13 SUMMARY FOR GLOBAL PARP INHIBITOR MARKET (2020-2025)

13.1 PARP Inhibitor Market Size

13.2 PARP Inhibitor Market by End Use

13.3 Competition by Players/Suppliers

13.4 PARP Inhibitor Market Size by Type

CHAPTER 14 GLOBAL PARP INHIBITOR MARKET FORECAST (2025-2030)

14.1 PARP Inhibitor Market Size Forecast

14.2 PARP Inhibitor Application Forecast

14.3 Competition by Players/Suppliers

14.4 PARP Inhibitor Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

15.1 Merck & Co.

15.1.1 Company Profile

15.1.2 Main Business and PARP Inhibitor Information

15.1.3 SWOT Analysis of Merck & Co.

15.1.4 Merck & Co. PARP Inhibitor Revenue, Gross Margin and Market Share
(2020-2025)

15.2 GlaxoSmithKline

15.2.1 Company Profile

15.2.2 Main Business and PARP Inhibitor Information

15.2.3 SWOT Analysis of GlaxoSmithKline

15.2.4 GlaxoSmithKline PARP Inhibitor Revenue, Gross Margin and Market Share
(2020-2025)

15.3 Pfizer

15.3.1 Company Profile

15.3.2 Main Business and PARP Inhibitor Information

15.3.3 SWOT Analysis of Pfizer

15.3.4 Pfizer PARP Inhibitor Revenue, Gross Margin and Market Share (2020-2025)

15.4 pharma& Schweiz GmbH

15.4.1 Company Profile

15.4.2 Main Business and PARP Inhibitor Information

15.4.3 SWOT Analysis of pharma& Schweiz GmbH

15.4.4 pharma& Schweiz GmbH PARP Inhibitor Revenue, Gross Margin and Market
Share (2020-2025)

Please ask for sample pages for full companies list

Tables & Figures

TABLES AND FIGURES

Table Abbreviation and Acronyms

Table Research Scope of PARP Inhibitor Report

Table Data Sources of PARP Inhibitor Report

Table Major Assumptions of PARP Inhibitor Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure PARP Inhibitor Picture

Table PARP Inhibitor Classification

Table PARP Inhibitor Applications

Table Drivers of PARP Inhibitor Market

Table Restraints of PARP Inhibitor Market

Table Opportunities of PARP Inhibitor Market

Table Threats of PARP Inhibitor Market

Table Raw Materials Suppliers

Table Different Production Methods of PARP Inhibitor

Table Cost Structure Analysis of PARP Inhibitor

Table Key End Users

Table Latest News of PARP Inhibitor Market

Table Merger and Acquisition

Table Planned/Future Project of PARP Inhibitor Market

Table Policy of PARP Inhibitor Market

Table 2020-2030 North America PARP Inhibitor Market Size

Figure 2020-2030 North America PARP Inhibitor Market Size and CAGR

Table 2020-2030 North America PARP Inhibitor Market Size by Application

Table 2020-2025 North America PARP Inhibitor Key Players Revenue

Table 2020-2025 North America PARP Inhibitor Key Players Market Share

Table 2020-2030 North America PARP Inhibitor Market Size by Type

Table 2020-2030 United States PARP Inhibitor Market Size

Table 2020-2030 Canada PARP Inhibitor Market Size

Table 2020-2030 Mexico PARP Inhibitor Market Size

Table 2020-2030 South America PARP Inhibitor Market Size

Figure 2020-2030 South America PARP Inhibitor Market Size and CAGR

Table 2020-2030 South America PARP Inhibitor Market Size by Application

Table 2020-2025 South America PARP Inhibitor Key Players Revenue

Table 2020-2025 South America PARP Inhibitor Key Players Market Share

Table 2020-2030 South America PARP Inhibitor Market Size by Type

Table 2020-2030 Brazil PARP Inhibitor Market Size
Table 2020-2030 Argentina PARP Inhibitor Market Size
Table 2020-2030 Asia & Pacific PARP Inhibitor Market Size
Figure 2020-2030 Asia & Pacific PARP Inhibitor Market Size and CAGR
Table 2020-2030 Asia & Pacific PARP Inhibitor Market Size by Application
Table 2020-2025 Asia & Pacific PARP Inhibitor Key Players Revenue
Table 2020-2025 Asia & Pacific PARP Inhibitor Key Players Market Share
Table 2020-2030 Asia & Pacific PARP Inhibitor Market Size by Type
Table 2020-2030 China PARP Inhibitor Market Size
Table 2020-2030 India PARP Inhibitor Market Size
Table 2020-2030 Japan PARP Inhibitor Market Size
Table 2020-2030 South Korea PARP Inhibitor Market Size
Table 2020-2030 Southeast Asia PARP Inhibitor Market Size
Table 2020-2030 Australia PARP Inhibitor Market Size
Table 2020-2030 Europe PARP Inhibitor Market Size
Figure 2020-2030 Europe PARP Inhibitor Market Size and CAGR
Table 2020-2030 Europe PARP Inhibitor Market Size by Application
Table 2020-2025 Europe PARP Inhibitor Key Players Revenue
Table 2020-2025 Europe PARP Inhibitor Key Players Market Share
Table 2020-2030 Europe PARP Inhibitor Market Size by Type
Table 2020-2030 Germany PARP Inhibitor Market Size
Table 2020-2030 France PARP Inhibitor Market Size
Table 2020-2030 United Kingdom PARP Inhibitor Market Size
Table 2020-2030 Italy PARP Inhibitor Market Size
Table 2020-2030 Spain PARP Inhibitor Market Size
Table 2020-2030 Belgium PARP Inhibitor Market Size
Table 2020-2030 Netherlands PARP Inhibitor Market Size
Table 2020-2030 Austria PARP Inhibitor Market Size
Table 2020-2030 Poland PARP Inhibitor Market Size
Table 2020-2030 Russia PARP Inhibitor Market Size
Table 2020-2030 MEA PARP Inhibitor Market Size
Figure 2020-2030 MEA PARP Inhibitor Market Size and CAGR
Table 2020-2030 MEA PARP Inhibitor Market Size by Application
Table 2020-2025 MEA PARP Inhibitor Key Players Revenue
Table 2020-2025 MEA PARP Inhibitor Key Players Market Share
Table 2020-2030 MEA PARP Inhibitor Market Size by Type
Table 2020-2025 Global PARP Inhibitor Market Size by Region
Table 2020-2025 Global PARP Inhibitor Market Size Share by Region
Table 2020-2025 Global PARP Inhibitor Market Size by Application

Table 2020-2025 Global PARP Inhibitor Market Share by Application
Table 2020-2025 Global PARP Inhibitor Key Vendors Revenue
Figure 2020-2025 Global PARP Inhibitor Market Size and Growth Rate
Table 2020-2025 Global PARP Inhibitor Key Vendors Market Share
Table 2020-2025 Global PARP Inhibitor Market Size by Type
Table 2020-2025 Global PARP Inhibitor Market Share by Type
Table 2025-2030 Global PARP Inhibitor Market Size by Region
Table 2025-2030 Global PARP Inhibitor Market Size Share by Region
Table 2025-2030 Global PARP Inhibitor Market Size by Application
Table 2025-2030 Global PARP Inhibitor Market Share by Application
Table 2025-2030 Global PARP Inhibitor Key Vendors Revenue
Figure 2025-2030 Global PARP Inhibitor Market Size and Growth Rate
Table 2025-2030 Global PARP Inhibitor Key Vendors Market Share
Table 2025-2030 Global PARP Inhibitor Market Size by Type
Table 2025-2030 PARP Inhibitor Global Market Share by Type
Table Merck & Co. Information
Table SWOT Analysis of Merck & Co.
Table 2020-2025 Merck & Co. PARP Inhibitor Revenue Gross Profit Margin
Figure 2020-2025 Merck & Co. PARP Inhibitor Revenue and Growth Rate
Figure 2020-2025 Merck & Co. PARP Inhibitor Market Share
Table GlaxoSmithKline Information
Table SWOT Analysis of GlaxoSmithKline
Table 2020-2025 GlaxoSmithKline PARP Inhibitor Revenue Gross Profit Margin
Figure 2020-2025 GlaxoSmithKline PARP Inhibitor Revenue and Growth Rate
Figure 2020-2025 GlaxoSmithKline PARP Inhibitor Market Share
Table Pfizer Information
Table SWOT Analysis of Pfizer
Table 2020-2025 Pfizer PARP Inhibitor Revenue Gross Profit Margin
Figure 2020-2025 Pfizer PARP Inhibitor Revenue and Growth Rate
Figure 2020-2025 Pfizer PARP Inhibitor Market Share
Table pharma& Schweiz GmbH Information
Table SWOT Analysis of pharma& Schweiz GmbH
Table 2020-2025 pharma& Schweiz GmbH PARP Inhibitor Revenue Gross Profit Margin
Figure 2020-2025 pharma& Schweiz GmbH PARP Inhibitor Revenue and Growth Rate
Figure 2020-2025 pharma& Schweiz GmbH PARP Inhibitor Market Share

.....

I would like to order

Product name: PARP Inhibitor Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Product link: <https://marketpublishers.com/r/P0D7E9858458EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P0D7E9858458EN.html>